{{knowledge objective
|Identifiant=OIC-063-15-B
|Item_parent=Adolescent and adult schizophrenic disorders
|Item_parent_short=Adolescent and adult schizophrenic disorders
|Rank=B
|Title=Knowing the general principles of management
|Description=None
|Rubric=Management
|Contributors=
|Order=15}}


===Elimination of a non-psychiatric diagnosis===

*Blood work-up (standard work-up with calcemia and TSHus)
*Urinary toxicology
*Cerebral imaging (particularly if there is a 1st<sup>episode</sup>, neurological warning signs or atypical manifestations).
*EEG useful for a first episode or later to rule out comititude.
*Assessment based on the patient's clinical history.

===Hospitalisation in a psychiatric unit===
If acute episode with behavioural problems, suicidal or heteroaggressive risk

===Pharmacological antipsychotic treatment===
Treatment of the acute episode which will be continued to maintain efficacy (prevention of a relapse of the episode) and then to prevent recurrence during remission.

Choice based on efficacy, tolerance and compliance with previous treatments.

Second-generation antipsychotics in first-line treatment

Objective: monotherapy, minimum effective and tolerated dose

Action time of 3 to 6 weeks

Minimum treatment of 2 years following the first episode

===Associated pharmacological treatment===
Short-term anxiolytic treatment (phenothiazines, such as cyamemazine or levomepromazine, or benzodiazepines)

===Psychosocial care===

*Therapeutic education for patients and their families
*Cognitive remediation programme and social and professional rehabilitation
*Implementation of ALD treatment
*Discussion of protective measures in the event of administrative and financial management difficulties

===Electrostimulation treatment===

*Electroconvulsive therapy or "ECT": can be used in cases of resistance to drug treatment or associated catatonic syndrome.
*Other possible treatments: transcranial magnetic resonance stimulation to combat residual hallucinations.